Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Livzon Pharmaceutical Group ( (HK:1513) ) has provided an announcement.
Livzon Pharmaceutical Group has agreed to a connected transaction involving a capital increase and equity transfer at its subsidiary Fluffy Buddy, under which Xinyou Maohai will inject RMB15 million into Fluffy Buddy and acquire Joincare’s 49% stake, resulting in Xinyou Maohai holding 52.56% and Livzon’s stake being diluted from 51% to 47.44%. As a result, Fluffy Buddy will cease to be consolidated into Livzon’s financial statements, and the deal is classified under Hong Kong Listing Rules as a deemed disposal and connected transaction subject only to reporting and announcement requirements, indicating a restructuring of Livzon’s exposure to this business without triggering shareholder approval or major disclosure obligations.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a Hong Kong-listed healthcare company engaged in the research, development, manufacturing and distribution of pharmaceutical products, operating within the broader medical and life sciences industry. Through various subsidiaries, it participates in specialized healthcare-related businesses, including investments in niche operators such as Fluffy Buddy, thereby expanding its footprint across different segments of the health and wellness market.
Average Trading Volume: 735,449
Technical Sentiment Signal: Hold
Current Market Cap: HK$32.19B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.